CD19-CAR T-cells
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
... for CD19 (CD19 CAR–T cells) has produced a high rate of complete remission (CR) in adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (B-ALL) ...
17
Targeted antibody mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
... transferred T cells are being evaluated in preclinical models and in clinical trials ...potent T cells is inevitably correlated with a higher risk of long-lasting adverse effects, revealing ...
12
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
... anti-BCMA CAR T cells alone failed to reliably eliminate in vitro clonogenicity (Figure ...B cells and plasma cells to maximize the likelihood of eliminating all aspects of the myeloma ...
15
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
... single cells residing in a nanowell, representing a more physiological environment than any other available single cell ...single cells for time-point study can be measured by ana- lyzing a serial of ...to ...
16
Metformin inhibits proliferation and cytotoxicity and induces apoptosis via AMPK pathway in CD19-chimeric antigen receptor-modified T cells
... on CD19-CAR T cells in vitro, next we were interested in determining whether metformin had the same role on suppressing the cytotoxicity of CD19-CAR T cells in ...
10
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
... FRα CAR T cells in vivo, we inoculated NSG mice with MDA-231 or ...MDA-231.FRα cells and allowed for tumor ...MDA-231 cells in mice, analogous to the known association between FRα ...
12
<p>Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells</p>
... T cells/kg (transduction efficiency was ...of CAR-T cells and underwent hypoten- sion requiring continuous vasopressors on day 3 and hypoxia requiring continuous nasal catheter oxygen ...
5
CAR therapy: the CD19 paradigm
... T cells. Like B cell aplasia, it is an anticipated consequence of CAR T cell activity that exhibits variable ...magnitude. CD19 CAR T cells often induce fever ...
10
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
... ALL cells, a penta-valent CD22 CAR was designed and expressed in the bi-specific CAR T ...the CAR T cells de- signed to simultaneously target CD19 and CD22 ...
11
<p>Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma</p>
... combining CAR-T cell therapy with DAC therapy, we tested whether pretreated lymphoma cells with DAC would in fl uence their suscept- ibility to CAR-T cell-mediated ...with ...
12
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
... of CAR-T cell therapy in CLL [60–62]. When encountering target cells, CAR-T cells are activated in a short time and release many kinds of cytokines such as interleukin (IL)-6, ...
12
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
... Siddiqi T, Lin Y, Timmerman J, Stiff PJ, Friedberg J, Flinn I, Goy A, Smith M, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Reagan ...
5
Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system
... manufacturing CD19 CAR T cells for clinical use with significantly decreased cost and labor in as short as 8 ...of cells for therapeutic doses, with a minimal starting cell ...these ...
14
Wang_unc_0153M_18926.pdf
... 3 T cells expressing J591 or HuVh show similar antitumor activities in ...cell). CD19.CAR-T cells, J591.CAR-T cells and ...HuVh.CAR-T cells ...
29
Rejection of Experimental Hodgkins Lymphoma by T Cells Engineered with a CD19 Chimeric Antigen Receptor
... T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) signaling domain for triggering cell activation are ...
9
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
... engineer T cells is by viral vector transduction, using either gamma-retroviral vector or lentiviral vector ...phase cells, and there have been several reports of insertional mutagenesis ...
7
CD19 CAR T cell product and disease attributes predict leukemia remission durability
... of T cell–intrinsic attri- butes of either the sorted apheresis starting material (SM) or final cellular product (FP) directly associated with the risk of treatment failure and postremission ...that T ...
11
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
... lack CD19 expression [9], the CNS complications might less probably result from direct interactions be- tween CD19+ cells and ...penetrating CAR T ...residual CD19+ leukemia ...
5
Original Article PiggyBac-modified CD19-expressing 4T1 cell line for the evaluation of CAR construct
... this T cell-based treatment can cause severe toxici- ...engineered CAR-T cells harm non- tumor cells because of on-target/off-tumor ...the CAR-T cells with strong ...
8
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... receptor-modified T-cell (CAR-T) therapy for B-cell lymphocyte malignancies targeting CD19 places it in a rapidly growing field in cancer immunotherapy for both hematological and solid ...
12